Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing

P Alvarez, E Carrillo, C Vélez, F Hita-Contreras, A Martínez-Amat, F Rodríguez-Serrano, H Boulaiz, R Ortiz, C Melguizo, J Prados, A Aránega, P Alvarez, E Carrillo, C Vélez, F Hita-Contreras, A Martínez-Amat, F Rodríguez-Serrano, H Boulaiz, R Ortiz, C Melguizo, J Prados, A Aránega

Abstract

Regulation of hematopoietic stem cell release, migration, and homing from the bone marrow (BM) and of the mobilization pathway involves a complex interaction among adhesion molecules, cytokines, proteolytic enzymes, stromal cells, and hematopoietic cells. The identification of new mechanisms that regulate the trafficking of hematopoietic stem/progenitor cells (HSPCs) cells has important implications, not only for hematopoietic transplantation but also for cell therapies in regenerative medicine for patients with acute myocardial infarction, spinal cord injury, and stroke, among others. This paper reviews the regulation mechanisms underlying the homing and mobilization of BM hematopoietic stem/progenitor cells, investigating the following issues: (a) the role of different factors, such as stromal cell derived factor-1 (SDF-1), granulocyte colony-stimulating factor (G-CSF), and vascular cell adhesion molecule-1 (VCAM-1), among other ligands; (b) the stem cell count in peripheral blood and BM and influential factors; (c) the therapeutic utilization of this phenomenon in lesions in different tissues, examining the agents involved in HSPCs mobilization, such as the different forms of G-CSF, plerixafor, and natalizumab; and (d) the effects of this mobilization on BM-derived stem/progenitor cells in clinical trials of patients with different diseases.

Figures

Figure 1
Figure 1
Factors favoring homing of HPSCs in the bone marrow. (A) Chemotactic factors independent of the SDF-1/CXCR4 axis gradient. (B) Triggering or modulating factors of the SDF-1/CXCR4 axis. HSPC: hematopoietic stem/progenitor cells; C3a: complement fraction C3a; C1q: complement fraction C1q; PMVs: platelet-derived microvesicles; HA: hyaluronic acid; TH: thrombin; MMP-2: metalloproteinase-2; MMP-9: metalloproteinase-9; MT1-MMP: membrane type-1 matrix metalloproteinase; SP1: sphingosine-1-phosphate; CP1: ceramide-1-phosphate.

References

    1. Gratwohl A, Baldomero H, Schmid O, et al. Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003. Bone Marrow Transplantation. 2005;36(7):575–590.
    1. Massberg S, Von Andrian UH. Novel trafficking routes for hematopoietic stem and progenitor cells. Annals of the New York Academy of Sciences. 2009;1176:87–93.
    1. Spradling A, Drummond-Barbosa D, Kai T. Stem cells find their niche. Nature. 2001;414(6859):98–104.
    1. Kopp HG, Avecilla ST, Hooper AT, Rafii S. The bone marrow vascular niche: home of HSC differentiation and mobilization. Physiology. 2005;20(5):349–356.
    1. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106(6):1901–1910.
    1. Baldomero H, Gratwohl M, Gratwohl A, et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation. 2011;46(4):485–501.
    1. Gratwohl A, Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Current Opinion in Hematology. 2009;16(6):420–426.
    1. Cohen Y, Nagler A. Umbilical cord blood transplantation—how, when and for whom? Blood Reviews. 2004;18(3):167–179.
    1. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100(5):1525–1531.
    1. Ringdén O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. Journal of Clinical Oncology. 2002;20(24):4655–4664.
    1. Ratajczak MZ, Kim CH, Abdel-Latif A, et al. A novel perspective on stem cell homing and mobilization: review on bioactive lipids as potent chemoattractants and cationic peptides as underappreciated modulators of responsiveness to SDF-1 gradients. Leukemia. 2012;26(1):63–72.
    1. Kränkel N, Spinettib G, Amadesic S, Madedduc P. Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacology Therapeutics. 2011;129(1):62–81.
    1. Campbell TB, Hangoc G, Liu Y, Pollok K, Broxmeyer HE. Inhibition of CD26 in human cord blood CD34+ cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells and Development. 2007;16(3):347–353.
    1. Kawai T, Choi U, Liu P-C, Whiting-Theobald NL, Linton GF, Malech HL. Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34+ peripheral blood cells. Stem Cells and Development. 2007;16(3):361–370.
    1. Haghighat A, Weiss D, Whalin MK, Cowan DP, Taylor WR. Granulocyte colony-stimulating factor and granulocyte macrophage colony-stimulating factor exacerbate atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2007;115(15):2049–2054.
    1. Tura O, Crawford J, Barclay GR, et al. Granulocyte colony-stimulating factor (G-CSF) depresses angiogenesis in vivo and in vitro: implications for sourcing cells for vascular regeneration therapy. Journal of Thrombosis and Haemostasis. 2010;8(7):1614–1623.
    1. Chung HK, Ko EM, Kim SW, et al. Antiapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytes. Biochemistry and Molecular Biology Reports. 2012;458(127):742–747.
    1. Fu ZH, Dong W, Gai LY, Wang F, Ding R, Chen YD. Effect of erythropoietin combined with granulocyte-colony stimulating factor in the treatment of acute myocardial infarction in rats. Journal of Southern Medical University. 2011;31(1):17–22.
    1. Guo Y, Liu C, He J. Effect of combined therapy of granulocyte colony stimulating factor and bone marrow mesenchymal stem cells carrying hepatocyte growth factor gene on angiogenesis of myocardial infarction in rats. Chinese Journal of Reparative and Reconstructive Surgery. 2011;25(6):736–740.
    1. Pelus LM, Bian H, Fukuda S, Wong D, Merzouk A, Salari H. The CXCR4 agonist peptide, CTCE-0021, rapidly mobilizes polymorphonuclear neutrophils and hematopoietic progenitor cells into peripheral blood and synergizes with granulocyte colony-stimulating factor. Experimental Hematology. 2005;33(3):295–307.
    1. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–988.
    1. Méndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature. 2008;452(7186):442–447.
    1. Balabanian K, Lagane B, Infantino S, et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry. 2005;280(42):35760–35766.
    1. Qing M, Jones D, Springer TA. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999;10(4):463–471.
    1. Rankin SM. Chemokines and adult bone marrow stem cells. Immunology Letters. 2012;145:147–254.
    1. Perez LE, Alpdogan O, Shieh J-H, et al. Increased plasma levels of stromal-derived factor-1 (SDF-1/CXCL12) enhance human thrombopoiesis and mobilize human colony-forming cells (CFC) in NOD/SCID mice. Experimental Hematology. 2004;32(3):300–307.
    1. Flomenberg N, Devine SM, DiPersio JF, et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005;106(5):1867–1874.
    1. Gangadhar T, Nandi S, Salgia R. The role of chemokine receptor CXCR4 in lung cancer. Cancer Biology and Therapy. 2010;9(6):409–416.
    1. Zabel BA, Lewén S, Berahovich RD, Jaén JC, Schall TJ. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Molecular Cancer. 2011;10, article no. 73
    1. Liles WC, Broxmeyer HE, Rodger E, et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood. 2003;102(8):2728–2730.
    1. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. Journal of Biological Chemistry. 2008;283(7):4283–4294.
    1. Schutyser E, Su Y, Yu Y, et al. Hypoxia enhances CXCR4 expression in human microvascular endothelial cells and human melanoma cells. European Cytokine Network. 2007;18(2):59–70.
    1. Dar A, Kollet O, Lapidot T. Mutual, reciprocal SDF-1/CXCR4 interactions between hematopoietic and bone marrow stromal cells regulate human stem cell migration and development in NOD/SCID chimeric mice. Experimental Hematology. 2006;34(8):967–975.
    1. Vagima Y, Lapid K, Kollet O, Goichberg P, Alon R, Lapidot T. Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. Methods in Molecular Biology. 2011;750:277–289.
    1. Hattori K, Heissig B, Tashiro K, et al. Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood. 2001;97(11):3354–3360.
    1. Walter DH, Rochwalsky U, Reinhold J, et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(2):275–282.
    1. Kim CH, Wu W, Wysoczynski M, et al. Conditioning for hematopoietic transplantation activates the complement cascade and induces a proteolytic environment in bone marrow: a novel role for bioactive lipids and soluble C5b-C9 as homing factors. Leukemia. 2012;26(1):106–116.
    1. Lee HM, Wu W, Wysoczynski M, et al. Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia. 2009;23(11):2052–2062.
    1. Avigdor A, Goichberg P, Shivtiel S, et al. CD44 and hyaluronic acid cooperate with SDF-1 in the trafficking of human CD34+ stem/progenitor cells to bone marrow. Blood. 2004;103(8):2981–2989.
    1. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of Kit-ligand. Cell. 2002;109(5):625–637.
    1. Winkler IG, Lévesque J-P. Mechanisms of hematopoietic stem cell mobilization: when innate immunity assails the cells that make blood and bone. Experimental Hematology. 2006;34(8):996–1009.
    1. Lévesque J-P, Hendy J, Takamatsu Y, Williams B, Winkler IG, Simmons PJ. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Experimental Hematology. 2002;30(5):440–449.
    1. Castellino FJ, Ploplis VA. Structure and function of the plasminogen/plasmin system. Thrombosis and Haemostasis. 2005;93(4):647–654.
    1. Gong Y, Hoover-Plow J. The plasminogen system regulating stem cell mobilization. Journal of Biomedicine and Biotechnology. 2012;2012:7 pages.437920
    1. Montuori N, Carriero MV, Salzano S, Rossi G, Ragno P. The cleavage of the urokinase receptor regulates its multiple functions. Journal of Biological Chemistry. 2002;277(49):46932–46939.
    1. Gazitt Y. Homing and mobilization of hematopoietic stem cells and hematopoietic cancer cells are mirror image processes, utilizing similar signaling pathways and occuring concurrently: circulating cancer cells constitute an ideal target for concurrent treatment with chemotherapy and antilineage-specific antibodies. Leukemia. 2004;18(1):1–10.
    1. Craddock CF, Nakamoto B, Andrews RG, Priestley GV, Papayannopoulou T. Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice. Blood. 1997;90(12):4779–4788.
    1. Chigaev A, Winter SS, Sklar LA. Is prolonged stem cell mobilization detrimental for hematopoiesis? Medical Hypotheses. 2011;77(6):1111–1113.
    1. Ulyanova T, Scott LM, Priestley GV, et al. VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin. Blood. 2005;106(1):86–94.
    1. Lévesque J-P, Hendy J, Winkler IG, Takamatsu Y, Simmons PJ. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Experimental Hematology. 2003;31(2):109–117.
    1. Kimura Y, Ding B, Imai N, Nolan DJ, Butler JM, Rafii S. C-kit-mediated functional positioning of stem cells to their niches is essential for maintenance and regeneration of adult hematopoiesis. PLoS One. 2011;6(10)e26918
    1. Bonig H, Priestley GV, Oehler V, Papayannopoulou T. Hematopoietic Progenitor Cells (HPC) from Mobilized Peripheral Blood Display Enhanced Migration and Marrow Homing Compared to Steady-State Bone Marrow HPC. Experimental Hematology. 2007;35(2):326–334.
    1. Wright DE, Wagers AJ, Pathak Gulati A, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science. 2001;294(5548):1933–1936.
    1. Broxmeyer HE, Orschell CM, Clapp DW, et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. Journal of Experimental Medicine. 2005;201(8):1307–1318.
    1. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003;102(4):1340–1346.
    1. Han J, Koh YJ, Moon HR, et al. Adipose tissue is an extramedullary reservoir for functional hematopoietic stem and progenitor cells. Blood. 2010;115(5):957–964.
    1. Pitchford SC, Hahnel MJ, Jones CP, Rankin SM. Troubleshooting: quantification of mobilization of progenitor cell subsets from bone marrow in vivo. Journal of Pharmacological and Toxicological Methods. 2010;61(2):113–121.
    1. Cashen AF, Link D, Devine S, DiPersio J. Cytokines and stem cell mobilization for autologous and allogeneic transplantation. Current hematology reports. 2004;3(6):406–412.
    1. Brown RA, Adkins D, Goodnough LT, et al. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies. Journal of Clinical Oncology. 1997;15(9):3067–3074.
    1. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. Journal of Clinical Oncology. 2000;18(6):1360–1377.
    1. Greenbaum AM, Link DC. Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilization. Leukemia. 2011;25(2):211–217.
    1. Cencioni C, Capogrossi MC, Napolitano M. The SDF-1/CXCR4 axis in stem cell preconditioning. Cardiovascular Research. 2012;94(3):400–407.
    1. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988;72(6):2074–2081.
    1. Lefrère F, Bernard M, Audat F, et al. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: a retrospective study of 126 patients. Leukemia and Lymphoma. 1999;35(5-6):501–505.
    1. Fischer JC, Frick M, Wassmuth R, Platz A, Punzel M, Wernet P. Superior mobilisation of haematopoietic progenitor cells with glycosylated G-CSF in male but not female unrelated stem cell donors. British Journal of Haematology. 2005;130(5):740–746.
    1. To LB, Levesque J-P, Herbert KE. How I treat patients who mobilize hematopoietic stem cells poorly. Blood. 2011;118(17):4530–4540.
    1. Motabi IH, DiPersio JF. Advances in stem cell mobilization. Blood Reviews. 2012;26(6):267–278.
    1. Fruehauf S, Schmitt K, Veldwijk MR, et al. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. British Journal of Haematology. 1999;105(3):786–794.
    1. Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. Experimental Hematology. 2011;39(7):723–729.
    1. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology. 1995;13(10):2547–2555.
    1. Gertz MA, Wolf RC, Micallef INM, Gastineau DA. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplantation. 2010;45(9):1396–1403.
    1. Maziarz RT, Nademanee AP, Micallef IN, et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biology of Blood and Marrow Transplantation. 2013;19(4):670–675.
    1. Hashimoto S, Itoh M, Nishimura M, Asai T. Effect of filgrastim administration for steady-state mobilization of peripheral blood stem cells. Therapeutic Apheresis. 2002;6(6):431–436.
    1. Kröger N, Renges H, Krüger W, et al. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. British Journal of Haematology. 2000;111(3):761–765.
    1. Ings SJ, Balsa C, Leverett D, Mackinnon S, Linch DC, Watts MJ. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used. British Journal of Haematology. 2006;134(5):517–525.
    1. Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells. Biology of Blood and Marrow Transplantation. 1997;3(1):45–49.
    1. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. Journal of Pediatric Hematology/Oncology. 2004;26(11):761–763.
    1. Ratajczak MZ, Lee H, Wysoczynski M, et al. Novel insight into stem cell mobilization-Plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia. 2010;24(5):976–985.
    1. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet. 1992;339(8794):640–644.
    1. Schwartzberg LS, Birch R, Hazelton B, et al. Peripheral blood stem cell mobilization by chemotherapy with and without recombinant human granulocyte colony-stimulating factor. Journal of hematotherapy. 1992;1(4):317–327.
    1. Dazzi C, Cariello A, Rosti G, et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin’s lymphoma? Leukemia and Lymphoma. 2000;39(3-4):301–310.
    1. Dingli D, Nowakowski GS, Dispenzieri A, et al. Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma. Clinical Lymphoma and Myeloma. 2006;6(5):384–388.
    1. Kim S, Kim H-J, Park JS, et al. Prospective randomized comparative observation of single- vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin’s lymphoma. Annals of Hematology. 2005;84(11):742–747.
    1. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. American Journal of Hematology. 2009;84(6):335–337.
    1. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplantation. 2004;33(9):907–912.
    1. Wuchter P, Ran D, Bruckner T, et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biology of Blood and Marrow Transplantation. 2010;16(4):490–499.
    1. Olivieri A, Marchetti M, Lemoli R, et al. Proposed definition of ’poor mobilizer’ in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplantation. 2012;47(3):342–351.
    1. Petit I, Szyper-Kravitz M, Nagler A, et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nature Immunology. 2002;3(7):687–694.
    1. Bensinger W, DiPersio JF, McCarty JM. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplantation. 2009;43(3):181–195.
    1. Demirer T, Buckner CD, Gooley T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplantation. 1996;17(6):937–941.
    1. Pusic I, Jiang SY, Landua S, et al. Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation. Biology of Blood and Marrow Transplantation. 2008;14(9):1045–1056.
    1. Jantunen E, Itälä M, Siitonen T, et al. Blood stem cell mobilization and collection in patients with chronic lymphocytic leukaemia: a nationwide analysis. Bone Marrow Transplantation. 2008;41(3):239–244.
    1. Haas R, Möhle R, Frühauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 1994;83(12):3787–3794.
    1. Lysak D, Koza V, Steinerova K, Jindra P, Vozobulova V, Schutzova M. Mobilization of peripheral blood stem cells in CLL patients after front-line fludarabine treatment. Annals of Hematology. 2005;84(7):456–461.
    1. Laszlo D, Galieni P, Raspadori D, Tozzi M, Lauria F, Martinelli G. Fludarabine combination regimen severely affected peripheral blood stem cell mobilization. Acta Haematologica. 2004;111(4):228–229.
    1. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biology of Blood and Marrow Transplantation. 2009;15(6):718–723.
    1. Sevilla J, Guillén M, Castillo A, et al. Defining “poor mobilizer” in pediatric patients who need an autologous peripheral blood progenitor cell transplantation. Cytotherapy. 2013;15(1):132–137.
    1. Han X, Ma L, Zhao L, et al. Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14-year experience of a single-center study. Journal of Clinical Apheresis. 2012;27(2):64–74.
    1. Fu P, Bagai RK, Meyerson H, et al. Pre-mobilization therapy blood CD34+ cell count predicts the likelihood of successful hematopoietic stem cell mobilization. Bone Marrow Transplantation. 2006;38(3):189–196.
    1. Suzuya H, Watanabe T, Nakagawa R, et al. Factors associated with granulocyte colony-stimulating factor-induced peripheral blood stem cell yield in healthy donors. Vox Sanguinis. 2005;89(4):229–235.
    1. Zubair AC, Grant R, Wu W, et al. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008;48(6):1106–1114.
    1. Molineux G, Pojda Z, Hampson IN, Lord BI, Dexter TM. Transplantation potential of peripheral blood stem cells induced by granulocyte colony-stimulating factor. Blood. 1990;76(10):2153–2158.
    1. Gordan LN, Sugrue MW, Lynch JW, et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leukemia and Lymphoma. 2003;44(5):815–820.
    1. Ferraro F, Lymperi S, Méndez-Ferrer S, et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Science translational medicine. 2011;3(104, article 104ra101)
    1. Lysák D, Hrabětová M, Vrzalová J, et al. Changes of cytokine levels during granulocyte-colony-stimulating factor stem cell mobilization in healthy donors: association with mobilization efficiency and potential predictive significance. Transfusion. 2011;51(2):319–327.
    1. Cashen AF, Nervi B, DiPersio J. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent. Future Oncology. 2007;3(1):19–27.
    1. Devine SM, Flomenberg N, Vesole DH, et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin’s lymphoma. Journal of Clinical Oncology. 2004;22(6):1095–1102.
    1. Duarte RF, Shaw BE, Marín P, et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplantation. 2011;46(1):52–58.
    1. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45(3):295–300.
    1. Douglas KW, Parker AN, Hayden PJ, et al. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplantation. 2012;47(1):18–23.
    1. Abhyankar S, Dejarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplantation. 2012;47(4):483–487.
    1. Kessans MR, Gatesman ML, Kockler DR. Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy. 2010;30(5):485–492.
    1. Jantunen E. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opinion on Biological Therapy. 2011;11(9):1241–1248.
    1. Cashen A, Lopez S, Gao F, et al. A Phase II Study of Plerixafor (AMD3100) plus G-CSF for Autologous Hematopoietic Progenitor Cell Mobilization in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation. 2008;14(11):1253–1261.
    1. Calandra G, McCarty J, McGuirk J, et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplantation. 2008;41(4):331–338.
    1. Micallef IN, Stiff PJ, DiPersio JF, et al. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin Lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biology of Blood and Marrow Transplantation. 2009;15(12):1578–1586.
    1. Steinberg M, Silva M. Plerixafor: a chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-hodgkin’s lymphoma or multiple myeloma. Clinical Therapeutics. 2010;32(5):821–843.
    1. Stiff P, Micallef I, McCarthy P, et al. Treatment with plerixafor in non-Hodgkin’s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biology of Blood and Marrow Transplantation. 2009;15(2):249–256.
    1. Jantunen E, Kvalheim G. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. European Journal of Haematology. 2010;85(6):463–471.
    1. Dugan MJ, Maziarz RT, Bensinger WI, et al. Safety and preliminary efficacy of plerixafor (mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin’s lymphoma undergoing stem cell mobilization. Bone Marrow Transplantation. 2010;45(1):39–47.
    1. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe Β-thalassemia results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Molecular Therapy. 2012;20(1):230–238.
    1. Saure C, Weigelt C, Schroeder T, et al. Plerixafor enables successful hematopoietic stem cell collection in an extensively pretreated patient with testicular cancer. Acta Haematologica. 2010;124(4):235–238.
    1. Sinha S, Gastineau D, Micallef I, et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplantation. 2011;46(7):943–949.
    1. Awan FT, Kochuparambil ST, Deremer D, et al. Plerixafor salvage is safe and effective in hard-to-mobilize patients undergoing chemotherapy and Filgrastim-based peripheral blood progenitor cell mobilization. Journal of Oncology. 2012;2012:5 pages.931071
    1. Zohren F, Toutzaris D, Klärner V, Hartung H-P, Kieseier B, Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34 hematopoietic progenitor cells in humans. Blood. 2008;111(7):3893–3895.
    1. Bonig H, Wundes A, Chang K-H, Lucas S, Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood. 2008;111(7):3439–3441.
    1. Schmitt S, Weinhold N, Dembowsky K, et al. First results of a phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HCS) in multiple myeloma (MM) Blood. 116(abstract 824)(21) Proceedings of the ASH Annual Meeting Abstracts, 2010.
    1. Nagler A, Shimoni A, Avivi I, et al. BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation. Blood. 116(abstract 2260)(21) Proceedings of the ASH Annual Meeting Abstracts, 2010.
    1. Ghadge SK, Mühlstedt S, Özcelik C, Bader M. SDF-1α as a therapeutic stem cell homing factor in myocardial infarction. Pharmacology and Therapeutics. 2011;129(1):97–108.
    1. Wang Y, Luther K. Genetically manipulated progenitor/stem cells restore function to the infarcted heart via the SDF-1α/CXCR4 signaling pathway. Progress in Molecular Biology and Translational Science. 2012;111:265–284.
    1. Wen Z, Zheng S, Zhou C, Wang J, Wang T. Repair mechanisms of bone marrow mesenchymal stem cells in myocardial infarction. Journal of Cellular and Molecular Medicine. 2011;15(5):1032–1043.
    1. Karapetyan AV, Klyachkin YM, Selim S, et al. Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow derived stem cell in patients with acute myocardial infarction. Stem Cells and Development. 2013;22(11):1645–1656.
    1. Wen Z, Zheng S, Zhou C, Yuan W, Wang J, Wang T. Bone marrow mesenchymal stem cells for post-myocardial infarction cardiac repair: microRNAs as novel regulators. Journal of Cellular and Molecular Medicine. 2012;16(4):657–671.
    1. Hong SJ, Choi SC, Kim JS, et al. Low-dose versus moderate-dose atorvastatin after acute myocardial infarction: 8-Month effects on coronary flow reserve and angiogenic cell mobilisation. Heart. 2010;96(10):756–764.
    1. Harada M, Qin Y, Takano H, et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Medicine. 2005;11(3):305–311.
    1. Zohlnhöfer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. Journal of the American Medical Association. 2006;295(9):1003–1010.
    1. Campbell TB, Sevin A, Coombs RW, et al. Changes in human immunodeficiency virus type 1 virus lead during mobilization and harvesting of hemopoietic progenitor cells. Blood. 2000;95(1):48–55.
    1. Schooley RT, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. Journal of Infectious Diseases. 2000;181(1):148–157.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner